1. Carvacrol-conjugated 3-Hydroxybenzoic Acids: Design, Synthesis, cardioprotective potential against doxorubicin-induced Cardiotoxicity, and ADMET study.
- Author
-
Retnosari R, Oh-Hashi K, Ugusman A, Zainalabidin S, Latip J, and Oka N
- Subjects
- Structure-Activity Relationship, Hydroxybenzoates chemistry, Hydroxybenzoates pharmacology, Hydroxybenzoates chemical synthesis, Molecular Structure, Humans, Cell Survival drug effects, Rats, Dose-Response Relationship, Drug, Cell Line, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Animals, Monoterpenes chemistry, Monoterpenes pharmacology, Monoterpenes chemical synthesis, Cymenes chemistry, Cymenes pharmacology, Cymenes chemical synthesis, Doxorubicin pharmacology, Drug Design, Cardiotonic Agents pharmacology, Cardiotonic Agents chemical synthesis, Cardiotonic Agents chemistry, Cardiotoxicity prevention & control
- Abstract
Carvacrol (CA) is a phenolic monoterpene renowned for its diverse pharmacological benefits, particularly its cardioprotective effects. Concurrently, phenolic acids have also demonstrated promise in mitigating drug-induced cardiotoxicity. Focusing on combating doxorubicin-induced cardiotoxicity (DIC), the research aims to synthesize novel cardioprotective agents by combining CA with 3-hydroxybenzoic acid (3HA). Doxorubicin, an anticancer drug, poses cardiovascular risks as its adverse effect, prompting the exploration of hybrid compounds. Various linker molecules, including alkyl and acyl with different carbon lengths, were investigated to understand their impact on bioactivity. In vitro testing on the DOX-induced H9c2 cell death model revealed the effectiveness of a CA conjugate in preserving cardiomyocyte viability. In silico analysis highlighted favorable drug-like properties and low toxicity of the conjugate. This study sheds light on molecular hybridization's potential in developing cardioprotective agents, emphasizing CA's pivotal role in combating DIC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF